Astec LifeSciences Limited has informed the Exchange regarding a press release dated April 27, 2026, titled "PRESS RELEASE".

Revenue Growth 20pctPat NegativeEbitda Margin ExpansionExceptional ItemResults View source PDF

ASTEC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-7.1%1-day move

₹748.80

prior close

₹758.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-2.6-3.2-3.5-3.4-7.1-7.2-3.8-8.7-6.5-5.2-0.5+2.4-4.6—

Up moveDown movePending

AI summary

Astec LifeSciences reported strong Q4 FY26 revenue growth of 34% year-on-year, with total income rising to ₹161.3 crore from ₹120.3 crore. The company achieved significant turnaround in EBITDA to ₹11.8 crore in Q4 FY26 from ₹6.3 crore in Q4 FY25, an 87% improvement. For the full year FY26, total income grew 17.1% to ₹453.2 crore from ₹386.9 crore, with EBITDA improving from a loss of ₹60.6 crore to breakeven at ₹0.5 crore. Despite these improvements, the company continues to report losses after tax - ₹7.7 crore in Q4 and ₹80.9 crore for FY26 (though improved from losses of ₹16.1 crore and ₹134.7 crore respectively in the prior year). The company also classified ₹2.1 crore as exceptional items related to new labour code regulations.

Likely market impact

The company shows encouraging signs of operational recovery with strong revenue growth and margin expansion, though shareholders should note that losses persist and full-year EBITDA remains barely breakeven.